Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
23 oct. 2024 06h00 HE
|
Revolution Medicines, Inc.
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday,...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
21 oct. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
07 oct. 2024 09h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
25 sept. 2024 03h00 HE
|
Medigene AG
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14 sept. 2024 07h30 HE
|
Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Companion Diagnostic Tests in Oncology Market Size is Set to Achieve USD 17.0 Billion by 2034, with 9.5% CAGR: Transparency Market Research Inc.
09 sept. 2024 20h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostic tests in oncology market (الاختبارات التشخيصية المصاحبة...
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
07 août 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
31 juil. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
11 juil. 2024 12h00 HE
|
Revolution Medicines, Inc.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
08 juil. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...